Back |
home / stock / bcyp / bcyp message board
Subject | By | Source | When |
---|---|---|---|
not enough to pay salary and some court filings... | ipnoob | investorshub | 03/04/2016 5:31:34 PM |
I do not understand..did they not, just get | notaclueyet | investorshub | 03/04/2016 5:29:13 PM |
bought and dump right away...the next thing will | ipnoob | investorshub | 03/04/2016 5:07:10 PM |
Blue Calypso Inc (OTCMKTS:$BCYP) CEO Andrew Levi bought | nhra3361 | investorshub | 03/03/2016 7:57:34 PM |
IPN, I expect you are right about the | someconcerns | investorshub | 03/03/2016 2:51:06 PM |
http://seekingalpha.com/news/3157626-blue-calypso-draws-350k-private-share-issuance sametime it' | ipnoob | investorshub | 03/03/2016 2:44:30 PM |
i believe it's on diff patents | ipnoob | investorshub | 03/03/2016 2:40:39 PM |
IBM suing$ GRPN as $BCYP is suing: | someconcerns | investorshub | 03/03/2016 2:38:09 PM |
congratulate to the bag holders for so long..finally | ipnoob | investorshub | 03/03/2016 2:38:05 PM |
Now that is some great news. | nhra3361 | investorshub | 03/03/2016 2:18:57 PM |
Federal Court of Appeals Overturns and Affirms PTAB | Pd102 | investorshub | 03/03/2016 1:06:46 PM |
Good news!! | wishmd | investorshub | 02/23/2016 2:14:14 PM |
News, Short Squeeze, Breakout and More Instantly...
SAB Biotherapeutics Inc Com Company Name:
BCYP Stock Symbol:
OTCMKTS Market:
SAB Biotherapeutics Inc Com Website:
SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human...
SAB highlights results from GLP toxicology study confirming SAB-142's mechanism of action at the 23rd Federation of Clinical Immunology Societies (FOCIS) Study shows SAB’s fully-human multi-target immune modulating therapeutic for treatment of Type 1 Diabetes is well tolerated ...
SIOUX FALLS, S.D., May 30, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies (fully-human polyc...